| Literature DB >> 32184869 |
Maryam Damercheli1, Mahdi Mahdi1, Bita Mehravi2, Mehdi Shafiee Ardestani3.
Abstract
Although metal-based anticancer drugs have been recognized as the most effective agents over the organic compounds, non-selectivity and high toxic effects have limited their applications in a way that only three Pt-analogues have progressed into clinical use. These problems have spurred chemists to develop different strategies based on alternative targets. This work focuses on predicting potency and mode of interactions of a series of salen type Schiff base transition metal complexes derived from meso-1,2-diphenyl-1,2-ethylenediamine, over some proteins (HDAC7, HDAC2, CatB, B-RAF kinase, TopII, RNR, TS, and rHA) using computational docking method, to be later considered as possible anticancer agents. The obtained results showed that all complexes exhibited higher affinity for HDAC7 than the other targets. Moreover, the bromo-derivatives of the copper compounds were more active on HDAC7 than the other derivatives. Such bromo compounds showed considerable interactions with Kinase, RNR, TS, and CatB. Contrary to Histone deacetylase (HAD)C7; HDAC2 was predicted to be relatively poor target. As expected, formation of the hydrophobic interactions between the metal complexes and the protein targets were essential for activity of the metal compounds. This study provides some more information for further optimizations and development of new metallodrugs as enzyme inhibitors for potential therapeutic agents.Entities:
Keywords: Anticancer; Docking; Histone deacetylase; Schiff base
Year: 2019 PMID: 32184869 PMCID: PMC7059031 DOI: 10.22037/ijpr.2019.12792.11151
Source DB: PubMed Journal: Iran J Pharm Res ISSN: 1726-6882 Impact factor: 1.696
Scheme 1Structures of the complexes used for docking into the active sites of the various receptors
Protein targets and pdbs selected for the study
|
|
|
|
|
|
|---|---|---|---|---|
| HDAC7 | 3COZ (2.1 Ǻ) | Octanedioic acid hydroxylamine phenylamide | A, B, C | B |
| HDAC2 | 3MAX (2.05 Ǻ) | N-(4-aminobiphenyl-3-yl)benzamide | A, B, C | A |
| CatB | 1CSB (2 Ǻ) | N-[(3R)-4-ethoxy-3-hydroxy-4- oxobutanoyl]- L-isoleucyl-L-proline CA030 | A, B | A, B |
| B-RAF kinase | 3Q4C (3.2 Ǻ) | C25 H16 Cl N3 O4 Ru | A, B | A |
| TopII | 1QZR (1.9 Ǻ) | (S)-4,4'-(1-methyl-1,2-ethanediyl)bis-2,6- piperazinedione | A, B | B |
| RNR | 4R1R (3.2 Ǻ) | guanosine-5'-diphosphate | A, B, C | C |
| TS | 2G8D (2.4 Ǻ) | 2'-deoxyuridine 5'-monodiphosphate | A | A |
| rHA | 1BMO (3.1 Ǻ) | n-acetyl-d-glucosamine | A, B | A |
The minimum binging energy of the docked structures (kcal mol-1).
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
| 1 | -6.28 | -8.14 | -6.50 | -6.77 | -6.28 | -7.59 | -7.33 | -6.87 |
| 2 | -6.45 | -9.60 | -6.42 | -8.19 | -7.09 | -7.38 | -7.07 | -8.31 |
| 3 | -6.41 | -7.89 | -6.10 | -6.92 | -7.15 | -7.05 | -7.13 | -6.78 |
| 4 | -7.29 | -8.33 | -6.20 | -7.87 | -7.32 | -7.07 | -7.11 | -6.89 |
| 5 | -6.19 | -8.20 | -6.01 | -7.67 | -6.34 | -6.98 | -6.03 | -7.08 |
| 6 | -6.07 | -7.50 | -6.02 | -7.40 | -6.39 | -7.00 | -5.95 | -6.56 |
| 7 | -6.50 | -7.52 | -5.78 | -6.76 | -6.91 | -7.32 | -6.68 | -6.61 |
| 8 | -6.95 | -8.55 | -7.09 | -7.67 | -7.25 | -7.61 | -7.85 | -7.25 |
| 9 | -6.14 | -7.05 | -4.80 | -6.50 | -5.81 | -5.67 | -5.65 | -5.70 |
| 10 | -6.76 | -9.50 | -6.06 | -8.12 | -6.79 | -8.25 | -7.07 | -7.85 |
| 11 | -7.03 | -8.31 | -6.31 | -6.13 | -6.14 | -7.18 | -6.11 | -6.53 |
| 12 | -6.84 | -8.10 | -6.51 | -6.58 | -6.11 | -6.50 | -7.91 | -7.18 |
| 13 | -6.55 | -8.94 | -6.00 | -7.69 | -6.68 | -7.65 | -6.92 | -7.17 |
| 14 | -6.38 | -8.87 | -6.01 | -8.13 | -6.54 | -7.79 | -7.26 | -7.40 |
The interactions of the binding site residues with the best inhibitor of the related receptor
|
|
|
|
|---|---|---|
|
| -7.29 | GLY198B |
|
| -7.09 | HIS33, PRO34, |
|
| -8.19 | CYS531, |
|
| -7.32 | ASP127, LYS133, SER96, ASN97, ASN99, ASP98, |
|
| -8.25 | SER625, LEU207, SER206, |
|
| -7.91 |
|
|
| -8.31 | GLU60, |
The first column shows the receptor and the number of its best active complex. The last column shows the surrounding residues of the docked complexes. Residues, which form hydrophobic interaction with the complexes are highlighted in bold and residues, which form hydrogen bonds are written in italic.
Figure 1The binding mods of the best inhibitor of the various related targets as predicted by docking method. The main residues involved in hydrophobic interactions were shown
The interactions of the binding site residues of HDAC7 with the complexes
|
|
|
|
|---|---|---|
| 1 | -8.14 |
|
| 2 | -9.6 |
|
| 3 | -7.89 |
|
| 4 | -8.33 |
|
| 5 | -8.2 |
|
| 6 | -7.5 |
|
| 7 | -7.52 |
|
| 8 | -8.55 |
|
| 9 | -7.05 |
|
| 10 | -9.5 |
|
| 11 | -8.31 |
|
| 12 | -8.06 |
|
| 13 | -8.94 |
|
| 14 | -8.87 |
|
The last column shows the surrounding residues of the docked complexes. Residues, which form hydrophobic and π-π stacking
interactions with the complexes are highlighted in bold and residues, which form hydrogen bonds are written in italic.
Figure 2Representative binding mods of the complexes 2 (left) and 10 (right) docked into the HDAC7 structure (PDB ID: 3COZ). The main residues involved in hydrophobic interactions were shown